The capital raise addresses near-term cash needs but at extreme dilutive cost for a $6M market cap company. Monitor for stockholder approval to unlock warrant exercise — Series E/F warrant shares could double the share count. The registration rights agreement imposes strict timelines; any filing delay triggers 2% monthly liquidated damages. Expect continued volatility as the warrants may be sold into any registration-driven liquidity.
Price Chart
Executive Summary
Dermata Therapeutics entered into a securities purchase agreement for a ~$3.36M private placement, issuing shares, pre-funded warrants, and Series E/F common warrants at ~$1.46-$1.47 per share. The company also entered into a registration rights agreement obligating it to register the resale of the shares and warrant shares. This dilutive capital raise signals cash needs at a $6M market cap company.
Key Financial Metrics
Key Facts
- Aggregate offering of ~$3,364,993.40 of shares and common warrants.
- Per share purchase price approximately $1.46-$1.47; Series E warrants exercisable at same price for 5 years post-stockholder approval, Series F for 24 months.
- Pre-funded warrants available with nominal $0.001 exercise price; common warrants exercisable only after stockholder approval.
- Registration rights agreement requires filing resale registration statement within 60 days (90-120 day effectiveness target) with liquidated damages up to 12% of subscription amount for delays.
- Company market cap is ~$6M; offering size represents >50% of market cap, causing severe dilution.
- Common warrant shares are exercisable only after stockholder approval; no immediate warrant overhang but significant future dilution potential.
Financial Impact
~$3.36M gross proceeds; likely 50%+ dilution relative to current market cap of ~$6M
Risk Factors
- Severe dilution from the offering and potential exercise of Series E/F warrants (up to 2× the shares sold).
- Stockholder approval required before common warrants become exercisable; failure to obtain could limit upside but also prevent dilution.
- Registration rights liquidated damages (up to 12% of subscription amount) add cash drain risk if SEC review is delayed.
- Low market cap (~$6M) and pre-revenue status make this a high-risk micro-cap; any adverse trial or regulatory news could impair value further.
- No specified use of proceeds beyond working capital / general corporate purposes — lack of clarity on cash runway extension.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-038647 |
| Exhibit: ex10-2.htm | 0001493152-26-038647 |
| Exhibit: ex4-2.htm | 0001493152-26-038647 |
| Exhibit: ex4-1.htm | 0001493152-26-038647 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 7d ago | EFFECT | $0.8000 $0.8640 | ▼ −8.00% | ▼ −9.18% | $0.7550 (+5.63%) |
Oct 9, 2026 18d ago | S-3 | $0.8896 $0.8599 | ▼ −3.34% | ▼ −3.33% | $0.7550 (−15.13%) |
Aug 17, 2026 10w ago | 8-K | $1.46 $1.43 | ▲ +2.05% | ▲ +1.38% | $0.7550 (+48.29%) |
Aug 5, 2026 11w ago | 8-K | $1.17 $1.11 | ▼ −5.13% | ▼ −4.97% | $0.7550 (−35.47%) |
Feb 25, 2026 34w ago | 8-K | $1.25 $1.20 | ▼ −4.00% | ▼ −3.52% | $0.7550 (−39.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers